Hainan Sparkle Therapeutics Co. Ltd. has disclosed fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Turn Biotechnologies Inc. has presented interim preclinical data that demonstrates treating T cells with its proprietary technologies can significantly increase their ability to kill cancer.
Researchers from Helmholtz-Zentrum Dresden-Rossendorf presented the discovery of novel small molecule-based radiotracers for PD-L1 PET or SPECT imaging.
Medshine Discovery Inc. has patented selenium-containing compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has disclosed pyrimidopyrazine compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
A recent Canwell Biotech Ltd. patent details the discovery of methionine aminopeptidase-2 (MetAP2) inhibitors reported to be useful for the treatment of cancer, diabetes, obesity, rheumatoid arthritis and psoriasis.
Yiteng Pharmaceutical Industry Taizhou Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Xi'an Xintong Medicine Research Co. Ltd. has synthesized 1,3-benzodioxolane-containing compounds acting as dual Bruton tyrosine kinase (BTK) and tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis and B-cell lymphoma.
RSS
